The 2-year R&D Project funded by the Innovation and Technology Fund (ITF) grant, administered by the Innovation and Technology Commission (ITC) of the Hong Kong Special Administrative Region (HKSAR) government, has been successfully completed. The project culminates in the establishment of drug screening platforms using an array of new-generation human heart tissue prototypes, and multiple patent applications for technologies developed within the project. The human ventricular cardiac anisotropic sheet (hvCAS) technology, developed within the project for detection of drug-induced arrhythmias, has been filed as a U.S. Provisional Patent application in August 2016, and the findings published in the prestigious bioengineering journal Advanced Materials in September 2016. Other publications and filings will be announced later in 2017. All Intellectual Property Rights developed within the project belong to Novoheart, and will contribute to the continual upgrade of the MyHeartTM Platform of drug screening tools.